Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations

Opinion
Video

Panelists discuss how the decision between quadruplet versus triplet therapy depends on multiple factors, including cytogenetic risk status, insurance coverage/drug access, patient fitness to tolerate additional toxicity, and the strength of evidence supporting improved outcomes with 4-drug combinations.

Video content above is prompted by the following:

What factors do you consider when choosing between quadruplet or triplet therapy in transplant-preferred newly diagnosed multiple myeloma (NDMM)?

Recent Videos
9 Experts are featured in this series.
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
Related Content